CRISPR stock decline is influenced by Editas Medicine's struggles, but CRSP remains strong with FDA approval and strategic ...

With that in mind, let's consider two stocks that haven't performed well recently and are now near their 52-week lows but ...

Analyst Gil Blum from Needham maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report) and keeping the price target at ...

In a report released yesterday, Alec Stranahan from Bank of America Securities maintained a Buy rating on Crispr Therapeutics AG (CRSP – ...

Shares of CRISPR Therapeutics CRSP have lost more than 30% in the past year. Though the stock soared at the onset of 2024, ...

If we assume all patients who began treatment with Casgevy last year progress to the administration stage, CRISPR and Vertex ...

CRISPR Therapeutics' lone approved product has ... Some investors believe you make money when you buy a stock, not when you sell it. The logic behind this idea is that investing in the right ...

We recently published a list of the 12 Biotech Stocks with the Biggest Upside Potential. In this article, we are going to ...

These cheap shares may be takeover targets in 2025, and as such, potentially offer shareholders the chance to earn outsized returns. The post 2 cheap shares that could be takeover targets in 2025 ...

and leveraging […] We recently compiled a list of the 10 Best Gene Therapy Stocks to Buy Right Now. In this article, we are going to take a look at where CRISPR Therapeutics AG (NASDAQ ...

We recently published a list of 10 Worst ARK Stocks To Buy According to Short Sellers. In this article, we are going to take a look at where CRISPR Therapeutics AG (NASDAQ:CRSP) stands against other ...

The most recent trading session ended with CRISPR Therapeutics AG (CRSP) standing at $38.36, reflecting a -1.26% shift from the previouse trading day's closing. The stock trailed the S&P 500, which ...